CLINICAL RESPONSE TO PAIN TREATMENT MEDICATIONS: CLINICAL EXOME PANEL (Sec. & CNVs) – 4 genes

LabGenetics

Delivery time

3-4 weeks

Sample

Blood

850,00€

The Clinical Response Panel for Analgesic Drugs evaluates genetic variants that influence the efficacy, metabolism, and toxicity risk of drugs used in the management of acute and chronic pain. It focuses on genes of the cytochrome P450 system (CYP2B6, CYP2C9, CYP2D6, CYP3A4) involved in the metabolism of opioids (codeine, tramadol, fentanyl, oxycodone, methadone) and nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, naproxen), allowing for dose adjustments and the prevention of adverse reactions or lack of therapeutic response.

Other tests

Exome panel analysis of 29 genes - idiopathic pulmonary fibrosis and surfactant protein deficiency

Exome panel analysis of 29 genes - idiopathic pulmonary fibrosis and surfactant protein deficiency

990,00€

511 gene analysis - epilepsy (using exome sequencing)

511 gene analysis - epilepsy (using exome sequencing)

1.495,00€

Exome analysis of AGXT, GRHPR, and HOGA1 genes - primary hyperoxaluria

Exome analysis of AGXT, GRHPR, and HOGA1 genes - primary hyperoxaluria

690,00€